 Maki Nakayama
Concepts (280)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Autoantigens | 13 | 2025 | 424 | 2.830 |
Why?
| | Receptors, Antigen, T-Cell | 12 | 2023 | 716 | 2.760 |
Why?
| | Protein Precursors | 5 | 2025 | 134 | 2.240 |
Why?
| | Diabetes Mellitus, Type 1 | 21 | 2025 | 3793 | 2.090 |
Why?
| | Insulin | 17 | 2025 | 2472 | 2.020 |
Why?
| | CD4-Positive T-Lymphocytes | 11 | 2021 | 1111 | 1.650 |
Why?
| | Islets of Langerhans | 9 | 2023 | 809 | 1.580 |
Why?
| | T-Lymphocytes | 9 | 2023 | 1996 | 1.380 |
Why?
| | Urogenital Abnormalities | 8 | 2025 | 71 | 1.320 |
Why?
| | Urinary Tract | 9 | 2025 | 51 | 1.250 |
Why?
| | Epitopes | 5 | 2025 | 476 | 1.240 |
Why?
| | Peptide Fragments | 9 | 2019 | 696 | 1.060 |
Why?
| | Epitopes, T-Lymphocyte | 4 | 2025 | 181 | 1.060 |
Why?
| | Proinsulin | 4 | 2025 | 52 | 1.010 |
Why?
| | Insulin-Secreting Cells | 5 | 2025 | 382 | 0.930 |
Why?
| | Nephrotic Syndrome | 7 | 2021 | 38 | 0.850 |
Why?
| | Autoimmunity | 10 | 2022 | 908 | 0.810 |
Why?
| | Hybridomas | 5 | 2020 | 233 | 0.800 |
Why?
| | Vesico-Ureteral Reflux | 6 | 2025 | 36 | 0.790 |
Why?
| | CD3 Complex | 2 | 2020 | 106 | 0.770 |
Why?
| | Disease Susceptibility | 2 | 2021 | 351 | 0.760 |
Why?
| | Lymphocyte Activation | 4 | 2020 | 1136 | 0.640 |
Why?
| | Peptides | 4 | 2023 | 971 | 0.640 |
Why?
| | Retroviridae | 1 | 2020 | 103 | 0.630 |
Why?
| | Immunoassay | 1 | 2020 | 110 | 0.620 |
Why?
| | Antigens | 3 | 2021 | 349 | 0.610 |
Why?
| | Immunomodulation | 1 | 2020 | 100 | 0.600 |
Why?
| | Cell Line, Transformed | 1 | 2018 | 145 | 0.570 |
Why?
| | Mice, Inbred NOD | 13 | 2019 | 599 | 0.550 |
Why?
| | Islets of Langerhans Transplantation | 1 | 2018 | 65 | 0.530 |
Why?
| | Allografts | 1 | 2018 | 148 | 0.520 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 3 | 2017 | 334 | 0.500 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2021 | 911 | 0.470 |
Why?
| | Podocytes | 6 | 2021 | 69 | 0.450 |
Why?
| | Animals | 33 | 2025 | 37328 | 0.440 |
Why?
| | Mice | 25 | 2025 | 17969 | 0.430 |
Why?
| | Mutation | 9 | 2025 | 4006 | 0.430 |
Why?
| | Graft Rejection | 1 | 2018 | 545 | 0.430 |
Why?
| | Pedigree | 9 | 2025 | 506 | 0.420 |
Why?
| | Genetic Predisposition to Disease | 7 | 2025 | 2366 | 0.410 |
Why?
| | Kidney | 11 | 2025 | 1482 | 0.400 |
Why?
| | Histocompatibility Antigens | 3 | 2021 | 107 | 0.390 |
Why?
| | Biomarkers | 2 | 2021 | 4180 | 0.340 |
Why?
| | Mutation, Missense | 4 | 2021 | 337 | 0.330 |
Why?
| | HLA Antigens | 2 | 2025 | 232 | 0.320 |
Why?
| | Macromolecular Substances | 1 | 2010 | 224 | 0.320 |
Why?
| | Histocompatibility Antigens Class II | 4 | 2018 | 367 | 0.310 |
Why?
| | Amino Acid Substitution | 5 | 2021 | 308 | 0.310 |
Why?
| | Antigen Presentation | 2 | 2025 | 213 | 0.300 |
Why?
| | Exome | 4 | 2025 | 235 | 0.290 |
Why?
| | Humans | 40 | 2025 | 141284 | 0.280 |
Why?
| | Alleles | 5 | 2021 | 878 | 0.260 |
Why?
| | DNA-Binding Proteins | 4 | 2025 | 1483 | 0.260 |
Why?
| | C-Peptide | 2 | 2018 | 168 | 0.250 |
Why?
| | Genetic Variation | 2 | 2021 | 993 | 0.240 |
Why?
| | Proteogenomics | 1 | 2025 | 5 | 0.240 |
Why?
| | Islet Amyloid Polypeptide | 2 | 2018 | 48 | 0.240 |
Why?
| | Immunotherapy | 2 | 2021 | 641 | 0.230 |
Why?
| | Mice, Knockout | 7 | 2023 | 3042 | 0.230 |
Why?
| | Open Reading Frames | 1 | 2025 | 132 | 0.230 |
Why?
| | Protein Binding | 5 | 2021 | 2233 | 0.220 |
Why?
| | Autoantibodies | 3 | 2010 | 1466 | 0.220 |
Why?
| | Neoplasms | 1 | 2020 | 2731 | 0.220 |
Why?
| | Transcription Factors | 3 | 2021 | 1706 | 0.210 |
Why?
| | Renal Insufficiency, Chronic | 3 | 2019 | 626 | 0.210 |
Why?
| | Alanine | 1 | 2004 | 159 | 0.210 |
Why?
| | Transgenes | 1 | 2004 | 185 | 0.210 |
Why?
| | Imidazolines | 1 | 2022 | 3 | 0.190 |
Why?
| | Urinary Bladder, Neurogenic | 1 | 2023 | 39 | 0.190 |
Why?
| | Forkhead Transcription Factors | 2 | 2020 | 200 | 0.190 |
Why?
| | Membrane Proteins | 2 | 2019 | 1144 | 0.190 |
Why?
| | HLA-A2 Antigen | 1 | 2021 | 47 | 0.180 |
Why?
| | Actins | 2 | 2021 | 426 | 0.180 |
Why?
| | Chemokine CCL3 | 1 | 2021 | 17 | 0.170 |
Why?
| | Chemokine CCL4 | 1 | 2021 | 22 | 0.170 |
Why?
| | Esophageal Atresia | 1 | 2021 | 26 | 0.170 |
Why?
| | Nephrosis | 1 | 2021 | 6 | 0.170 |
Why?
| | Uveitis | 1 | 2022 | 148 | 0.170 |
Why?
| | Tracheoesophageal Fistula | 1 | 2021 | 33 | 0.170 |
Why?
| | Hernia, Hiatal | 1 | 2021 | 40 | 0.170 |
Why?
| | Autoimmune Diseases | 2 | 2022 | 463 | 0.170 |
Why?
| | Hydroxybenzoates | 1 | 2020 | 11 | 0.160 |
Why?
| | Eye Abnormalities | 1 | 2020 | 17 | 0.160 |
Why?
| | Heterozygote | 4 | 2020 | 306 | 0.160 |
Why?
| | rho GTP-Binding Proteins | 1 | 2020 | 55 | 0.160 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 2 | 2011 | 101 | 0.160 |
Why?
| | Spinal Dysraphism | 1 | 2022 | 107 | 0.160 |
Why?
| | Ubiquinone | 1 | 2020 | 35 | 0.160 |
Why?
| | Homozygote | 4 | 2019 | 199 | 0.160 |
Why?
| | Microcephaly | 1 | 2021 | 101 | 0.160 |
Why?
| | Beryllium | 1 | 2021 | 161 | 0.160 |
Why?
| | Cross Reactions | 1 | 2020 | 132 | 0.160 |
Why?
| | Microfilament Proteins | 1 | 2020 | 133 | 0.160 |
Why?
| | HLA-DQ Antigens | 2 | 2019 | 173 | 0.160 |
Why?
| | NFATC Transcription Factors | 1 | 2020 | 94 | 0.160 |
Why?
| | Autonomic Nervous System Diseases | 1 | 2019 | 32 | 0.160 |
Why?
| | Genotype | 1 | 2004 | 1854 | 0.150 |
Why?
| | Anorectal Malformations | 1 | 2021 | 111 | 0.150 |
Why?
| | Collagen Type IV | 1 | 2019 | 28 | 0.150 |
Why?
| | Genes, Reporter | 1 | 2020 | 270 | 0.150 |
Why?
| | Berylliosis | 1 | 2021 | 193 | 0.150 |
Why?
| | Laminin | 1 | 2019 | 72 | 0.150 |
Why?
| | Phenotype | 4 | 2020 | 3172 | 0.150 |
Why?
| | Drug Resistance | 1 | 2019 | 149 | 0.150 |
Why?
| | Genetic Vectors | 1 | 2020 | 336 | 0.140 |
Why?
| | rab5 GTP-Binding Proteins | 1 | 2018 | 10 | 0.140 |
Why?
| | Diabetes Mellitus, Experimental | 2 | 2013 | 195 | 0.140 |
Why?
| | Congenital Abnormalities | 1 | 2019 | 105 | 0.140 |
Why?
| | Fraser Syndrome | 1 | 2018 | 1 | 0.140 |
Why?
| | Young Adult | 6 | 2021 | 13727 | 0.140 |
Why?
| | Protein Kinases | 1 | 2020 | 307 | 0.140 |
Why?
| | Chromogranin A | 1 | 2018 | 42 | 0.140 |
Why?
| | Female | 18 | 2025 | 75814 | 0.140 |
Why?
| | Heart Diseases | 1 | 2021 | 337 | 0.140 |
Why?
| | Tissue Donors | 1 | 2021 | 406 | 0.140 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2021 | 436 | 0.140 |
Why?
| | Immunization | 1 | 2020 | 402 | 0.140 |
Why?
| | Child | 8 | 2021 | 22390 | 0.130 |
Why?
| | T-Cell Antigen Receptor Specificity | 3 | 2012 | 51 | 0.130 |
Why?
| | Recombination, Genetic | 1 | 2018 | 205 | 0.130 |
Why?
| | Repressor Proteins | 1 | 2020 | 426 | 0.130 |
Why?
| | Receptors, Nicotinic | 1 | 2019 | 343 | 0.130 |
Why?
| | Kidney Diseases | 1 | 2021 | 409 | 0.130 |
Why?
| | Sarcoidosis, Pulmonary | 1 | 2017 | 86 | 0.120 |
Why?
| | Lung | 2 | 2021 | 4051 | 0.120 |
Why?
| | Genetic Association Studies | 3 | 2025 | 373 | 0.120 |
Why?
| | Gene Expression Regulation | 2 | 2018 | 2600 | 0.120 |
Why?
| | Genetic Testing | 1 | 2019 | 462 | 0.120 |
Why?
| | HLA-DR Antigens | 1 | 2016 | 222 | 0.120 |
Why?
| | Male | 16 | 2025 | 70140 | 0.120 |
Why?
| | Epigenesis, Genetic | 1 | 2020 | 661 | 0.120 |
Why?
| | Adolescent | 6 | 2021 | 22116 | 0.120 |
Why?
| | Glucocorticoids | 1 | 2019 | 534 | 0.110 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2017 | 633 | 0.110 |
Why?
| | DNA Mutational Analysis | 3 | 2019 | 396 | 0.100 |
Why?
| | Immunosuppressive Agents | 1 | 2019 | 855 | 0.100 |
Why?
| | Amino Acid Sequence | 4 | 2021 | 2146 | 0.100 |
Why?
| | Mice, Transgenic | 4 | 2009 | 2165 | 0.100 |
Why?
| | Disease Progression | 4 | 2019 | 2808 | 0.100 |
Why?
| | Complementarity Determining Regions | 1 | 2012 | 51 | 0.090 |
Why?
| | Crosses, Genetic | 2 | 2018 | 133 | 0.090 |
Why?
| | Mice, SCID | 2 | 2018 | 367 | 0.090 |
Why?
| | Germ-Line Mutation | 1 | 2012 | 168 | 0.080 |
Why?
| | Biomarkers, Tumor | 1 | 2018 | 1250 | 0.080 |
Why?
| | Organophosphorus Compounds | 1 | 2011 | 82 | 0.080 |
Why?
| | Xenopus | 2 | 2020 | 89 | 0.080 |
Why?
| | Glycine | 1 | 2011 | 187 | 0.080 |
Why?
| | Prediabetic State | 1 | 2013 | 251 | 0.080 |
Why?
| | Adoptive Transfer | 2 | 2013 | 219 | 0.080 |
Why?
| | Major Histocompatibility Complex | 1 | 2010 | 229 | 0.080 |
Why?
| | Immunodominant Epitopes | 1 | 2009 | 27 | 0.080 |
Why?
| | Consanguinity | 2 | 2019 | 49 | 0.070 |
Why?
| | Adult | 6 | 2021 | 39319 | 0.070 |
Why?
| | Spleen | 2 | 2013 | 512 | 0.070 |
Why?
| | Models, Molecular | 3 | 2021 | 1602 | 0.070 |
Why?
| | Age of Onset | 2 | 2019 | 536 | 0.070 |
Why?
| | RNA, Small Interfering | 2 | 2020 | 627 | 0.070 |
Why?
| | Signal Transduction | 1 | 2020 | 5116 | 0.060 |
Why?
| | Prognosis | 3 | 2019 | 4080 | 0.060 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2021 | 543 | 0.060 |
Why?
| | Poly I-C | 1 | 2005 | 59 | 0.060 |
Why?
| | Cells, Cultured | 3 | 2018 | 4149 | 0.060 |
Why?
| | Microinjections | 1 | 2004 | 85 | 0.060 |
Why?
| | Ovum | 1 | 2004 | 31 | 0.060 |
Why?
| | Cell Movement | 2 | 2020 | 962 | 0.060 |
Why?
| | Child, Preschool | 4 | 2021 | 11511 | 0.060 |
Why?
| | Thymus Gland | 2 | 2019 | 316 | 0.050 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 2021 | 873 | 0.050 |
Why?
| | Cell Line | 2 | 2021 | 2863 | 0.050 |
Why?
| | Interferon-alpha | 1 | 2005 | 195 | 0.050 |
Why?
| | Pancreas | 2 | 2019 | 326 | 0.050 |
Why?
| | Conserved Sequence | 2 | 2018 | 237 | 0.050 |
Why?
| | Hepatocyte Nuclear Factor 3-gamma | 1 | 2022 | 1 | 0.050 |
Why?
| | Forkhead Box Protein L2 | 1 | 2022 | 3 | 0.050 |
Why?
| | Hepatocyte Nuclear Factor 3-beta | 1 | 2022 | 12 | 0.050 |
Why?
| | Oleanolic Acid | 1 | 2022 | 9 | 0.050 |
Why?
| | Retinol-Binding Proteins | 1 | 2022 | 17 | 0.050 |
Why?
| | Models, Biological | 1 | 2010 | 1810 | 0.050 |
Why?
| | Mice, Inbred C57BL | 4 | 2020 | 5866 | 0.050 |
Why?
| | Eye Proteins | 1 | 2022 | 92 | 0.050 |
Why?
| | Interleukin-17 | 1 | 2022 | 119 | 0.050 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2022 | 94 | 0.050 |
Why?
| | Hemizygote | 1 | 2021 | 5 | 0.040 |
Why?
| | Infant | 3 | 2021 | 9820 | 0.040 |
Why?
| | Genes, X-Linked | 1 | 2021 | 20 | 0.040 |
Why?
| | Receptors, Interleukin | 1 | 2021 | 45 | 0.040 |
Why?
| | Pronephros | 1 | 2021 | 3 | 0.040 |
Why?
| | HSP90 Heat-Shock Proteins | 1 | 2021 | 47 | 0.040 |
Why?
| | Zinc Fingers | 1 | 2021 | 49 | 0.040 |
Why?
| | Xenopus laevis | 1 | 2021 | 104 | 0.040 |
Why?
| | Amphibian Proteins | 1 | 2020 | 1 | 0.040 |
Why?
| | Time Factors | 1 | 2012 | 6951 | 0.040 |
Why?
| | Cytoskeletal Proteins | 1 | 2021 | 154 | 0.040 |
Why?
| | HLA-DP beta-Chains | 1 | 2021 | 90 | 0.040 |
Why?
| | Pseudopodia | 1 | 2020 | 27 | 0.040 |
Why?
| | Gene Knockout Techniques | 1 | 2021 | 117 | 0.040 |
Why?
| | Morpholinos | 1 | 2020 | 29 | 0.040 |
Why?
| | Protein Stability | 1 | 2021 | 175 | 0.040 |
Why?
| | Enzyme Stability | 1 | 2020 | 71 | 0.040 |
Why?
| | Kidney Glomerulus | 1 | 2020 | 121 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2019 | 5222 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2004 | 1244 | 0.040 |
Why?
| | Cytoplasm | 1 | 2020 | 267 | 0.040 |
Why?
| | Glomerulosclerosis, Focal Segmental | 1 | 2020 | 45 | 0.040 |
Why?
| | Gene Knockdown Techniques | 1 | 2021 | 331 | 0.040 |
Why?
| | Animals, Genetically Modified | 1 | 2020 | 242 | 0.040 |
Why?
| | Chronic Disease | 2 | 2021 | 1807 | 0.040 |
Why?
| | Glomerular Basement Membrane | 1 | 2019 | 9 | 0.040 |
Why?
| | Methyltransferases | 1 | 2020 | 72 | 0.040 |
Why?
| | Larva | 1 | 2020 | 237 | 0.040 |
Why?
| | Web Browser | 1 | 2019 | 13 | 0.040 |
Why?
| | Kidney Diseases, Cystic | 1 | 2019 | 25 | 0.040 |
Why?
| | Ireland | 1 | 2019 | 30 | 0.040 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2019 | 156 | 0.040 |
Why?
| | Molecular Docking Simulation | 1 | 2019 | 111 | 0.040 |
Why?
| | Antioxidants | 1 | 2022 | 593 | 0.040 |
Why?
| | Medical History Taking | 1 | 2019 | 117 | 0.040 |
Why?
| | Phosphate-Binding Proteins | 1 | 2018 | 6 | 0.040 |
Why?
| | Specific Pathogen-Free Organisms | 1 | 2018 | 59 | 0.040 |
Why?
| | Lysosomes | 1 | 2019 | 129 | 0.040 |
Why?
| | Interleukin-6 | 1 | 2022 | 775 | 0.040 |
Why?
| | Infant, Newborn | 2 | 2021 | 6270 | 0.030 |
Why?
| | Gene Frequency | 1 | 2019 | 488 | 0.030 |
Why?
| | Databases, Genetic | 1 | 2019 | 244 | 0.030 |
Why?
| | Urogenital System | 1 | 2018 | 17 | 0.030 |
Why?
| | Cohort Studies | 2 | 2019 | 5809 | 0.030 |
Why?
| | Clone Cells | 1 | 2018 | 267 | 0.030 |
Why?
| | Genetic Loci | 1 | 2019 | 275 | 0.030 |
Why?
| | Mitochondrial Proteins | 1 | 2020 | 259 | 0.030 |
Why?
| | Receptors, Tumor Necrosis Factor, Member 25 | 1 | 2017 | 5 | 0.030 |
Why?
| | Homeodomain Proteins | 1 | 2021 | 514 | 0.030 |
Why?
| | Sex Distribution | 1 | 2018 | 381 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2020 | 738 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2018 | 343 | 0.030 |
Why?
| | Protein Domains | 1 | 2019 | 305 | 0.030 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2018 | 389 | 0.030 |
Why?
| | HLA-DRB1 Chains | 1 | 2017 | 110 | 0.030 |
Why?
| | Immune Tolerance | 1 | 2019 | 373 | 0.030 |
Why?
| | Exons | 1 | 2018 | 352 | 0.030 |
Why?
| | Extracellular Matrix Proteins | 1 | 2018 | 156 | 0.030 |
Why?
| | Calcium-Binding Proteins | 1 | 2018 | 213 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 1 | 2019 | 571 | 0.030 |
Why?
| | Drosophila melanogaster | 1 | 2018 | 234 | 0.030 |
Why?
| | Models, Animal | 1 | 2018 | 391 | 0.030 |
Why?
| | Mice, Inbred BALB C | 2 | 2011 | 1261 | 0.030 |
Why?
| | Family | 1 | 2020 | 677 | 0.030 |
Why?
| | Animals, Newborn | 1 | 2018 | 866 | 0.030 |
Why?
| | Evolution, Molecular | 1 | 2019 | 503 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2021 | 847 | 0.030 |
Why?
| | Blood Glucose | 1 | 2005 | 2286 | 0.030 |
Why?
| | Precision Medicine | 1 | 2019 | 435 | 0.030 |
Why?
| | Cytokines | 1 | 2022 | 2079 | 0.030 |
Why?
| | Acute Disease | 1 | 2017 | 1005 | 0.030 |
Why?
| | Computational Biology | 1 | 2019 | 663 | 0.030 |
Why?
| | Genomics | 1 | 2019 | 811 | 0.030 |
Why?
| | Mitochondria | 1 | 2020 | 962 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2018 | 1973 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2021 | 2122 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2020 | 3577 | 0.020 |
Why?
| | Baculoviridae | 1 | 2011 | 44 | 0.020 |
Why?
| | Incidence | 1 | 2018 | 2809 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2022 | 4414 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 333 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2019 | 3502 | 0.020 |
Why?
| | Small Molecule Libraries | 1 | 2011 | 99 | 0.020 |
Why?
| | Lymph Nodes | 1 | 2013 | 494 | 0.020 |
Why?
| | Antigens, Bacterial | 1 | 2011 | 124 | 0.020 |
Why?
| | Structure-Activity Relationship | 1 | 2011 | 569 | 0.020 |
Why?
| | Mass Screening | 1 | 2018 | 1309 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 849 | 0.020 |
Why?
| | Epitope Mapping | 1 | 2009 | 61 | 0.020 |
Why?
| | Risk Assessment | 1 | 2018 | 3522 | 0.020 |
Why?
| | Aged | 2 | 2019 | 24836 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2011 | 1182 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2011 | 2911 | 0.020 |
Why?
| | Metabolic Networks and Pathways | 1 | 2008 | 183 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2019 | 7948 | 0.020 |
Why?
| | Middle Aged | 2 | 2019 | 34658 | 0.020 |
Why?
| | Gene Expression | 1 | 2005 | 1490 | 0.010 |
Why?
| | Aging | 1 | 2005 | 1919 | 0.010 |
Why?
|
|
Nakayama's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|